Literature DB >> 9869482

Evolving therapeutic concepts and imaging in ischemic cardiomyopathy.

A Lahiri1, R Senior.   

Abstract

Entities:  

Mesh：

Year:  1998        PMID： 9869482     DOI： 10.1016/s1071-3581(98)90114-3

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  63 in total

1.  Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade.

Authors:  K Swedberg; A Hjalmarson; F Waagstein; I Wallentin
Journal:  Lancet       Date:  1979-06-30       Impact factor: 79.321

2.  A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure.

Authors:  U Elkayam; J Amin; A Mehra; J Vasquez; L Weber; S H Rahimtoola
Journal:  Circulation       Date:  1990-12       Impact factor: 29.690

3.  Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group.

Authors: 
Journal:  Lancet       Date:  1990-07-07       Impact factor: 79.321

4.  Neurohumoral Mechanisms in Congestive Heart Failure and the Role of Drugs with Multiple Actions: A Review of Carvedilol.

Authors:  Avijit Lahiri
Journal:  Am J Ther       Date:  1996-03       Impact factor: 2.688

5.  Prostacyclin therapy in patients with congestive heart failure.

Authors:  Y Yui; H Nakajima; C Kawai; T Murakami
Journal:  Am J Cardiol       Date:  1982-08       Impact factor: 2.778

6.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

7.  Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure.

Authors:  J N Barjon; J L Rouleau; D Bichet; C Juneau; J De Champlain
Journal:  J Am Coll Cardiol       Date:  1987-03       Impact factor: 24.094

8.  Results of coronary artery surgery in patients with poor left ventricular function (CASS).

Authors:  E L Alderman; L D Fisher; P Litwin; G C Kaiser; W O Myers; C Maynard; F Levine; M Schloss
Journal:  Circulation       Date:  1983-10       Impact factor: 29.690

9.  Myocardial perfusion-contraction matching. Implications for coronary heart disease and hibernation.

Authors:  J Ross
Journal:  Circulation       Date:  1991-03       Impact factor: 29.690

10.  Dobutamine echocardiography and thallium-201 imaging predict functional improvement after revascularisation in severe ischaemic left ventricular dysfunction.

Authors:  R Senior; B Glenville; S Basu; B S Sridhara; E Anagnostou; R Stanbridge; S J Edmondson; C E Handler; E B Raftery; A Lahiri
Journal:  Br Heart J       Date:  1995-10
View more
  4 in total

1.  The role of cardiac imaging in optimizing therapy in heart failure.

Authors:  A Lahiri
Journal:  J Nucl Cardiol       Date:  2000 Jan-Feb       Impact factor: 5.952

2.  Segmental pattern of myocardial sympathetic denervation in idiopathic dilated cardiomyopathy: relationship to regional wall motion and myocardial perfusion abnormalities.

Authors:  F I Parthenakis; V K Prassopoulos; S I Koukouraki; E A Zacharis; G F Diakakis; N K Karkavitsas; P E Vardas
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

3.  Predictors of improvement in left ventricular ejection fraction with carvedilol for congestive heart failure.

Authors:  J H O'Keefe; A Magalski; T L Stevens; D R Bresnahan; K Alaswad; S K Krueger; T M Bateman
Journal:  J Nucl Cardiol       Date:  2000 Jan-Feb       Impact factor: 5.952

4.  Impact of revascularization and myocardial viability determined by nitrate-enhanced Tc-99m sestamibi and Tl-201 imaging on mortality and functional outcome in ischemic cardiomyopathy.

Authors:  Roxy Senior; Sanjiv Kaul; Usha Raval; Avijit Lahiri
Journal:  J Nucl Cardiol       Date:  2002 Sep-Oct       Impact factor: 5.952
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.